Cohort studycited by the Tayebat archiveabstract only checked A-ODD-11 standard review
Ketoacidosis after starting SGLT2 drugs (letter)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Overview
Fralick M et al.. N Engl J Med 2017 · PMID 28591538 · DOI 10.1056/NEJMc1701990
Content not verified (no abstract).
Does the study support the specific claim? Unclear · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Risk of DKA after initiating an SGLT2 inhibitor (per title)
- How was the study done?
Research letter (no abstract in PubMed; full text not accessed)
- How many people, animals or samples were studied?
not verifiable; not verifiable
- What was actually found?
Not verified.
- How large was the observed effect?
not verified
- What do the results mean in everyday life?
See I-ODD-09.
- What are the study's limitations?
Not read; letter format
- What does it say about Elawady's specific claim?
Supports C-ODD-02 (direction).
- Do the results apply to Germany and Europe?
US data.
- What can explicitly not be concluded from this study?
Anything quantitative.
Scientific in-depth review
1. Full reference
- Authors
- Fralick M, Schneeweiss S, Patorno E
- Journal
- N Engl J Med
- Year
- 2017
- Identifier
- PMID 28591538 DOI 10.1056/NEJMc1701990
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Risk of DKA after initiating an SGLT2 inhibitor (per title)
3. Study design and population
- Study design
- Cohort study – Research letter (no abstract in PubMed; full text not accessed)
- Population
not verifiable
- Country
USA (per authors' affiliation; not verified)
- Period
not verifiable
- Sample size
not verifiable
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
SGLT2 inhibitor initiation
- Comparator
not verifiable (likely DPP-4 inhibitors; not verified)
- Endpoints
DKA
- Statistical methods
not verifiable
5. Actual results
- Results
No abstract available; numerical results not verified in this audit.
- Absolute risks
not reported
- Authors' conclusion
Not verifiable from the record.
6. Strengths
- NEJM letter by pharmacoepidemiology group
7. Weaknesses
- Not read; letter format
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Not read.
9. Assessment of the statistical interpretation
not assessable
10. Relevance to the specific claim
Supports C-ODD-02 (direction).
11. Independent contrary findings
12. Transferability to Germany and Europe
US data.
13. Overall methodological judgement
Consistent with later cohort; not verified.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not verifiable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- SGLT2 inhibitors such as dapagliflozin (Forxiga) can cause ketoacidosis, sometimes with normal or low blood glucose. – Studies supporting the claim
- Every major class of glucose-lowering drug (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists) carries a documented signal of serious harm in the peer-reviewed literature. – Studies supporting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography for 'oral-diabetes-drugs' without its own interpretation; used as support for the claim that every drug class carries documented harm.
- A. What was actually studied?
Risk of DKA after initiating an SGLT2 inhibitor (per title)
- B. What did the authors find?
Not verified.
- C. What conclusions do the authors themselves draw?
Not verifiable from the record.
- D. What does the archive derive from it?
Support for SGLT2 ketoacidosis.
- E. Is this derivation scientifically justified?
Not verifiable from abstract; direction consistent with the later multinational cohort (I-ODD-09).
- Adequacy of the interpretation (by the archive)
- not verifiable